Evidence map›Paper›PMID 34667144›Full record

ArticleTranslational psychiatry2021

A longitudinal study of gene expression in first-episode schizophrenia; exploring relapse mechanisms by co-expression analysis in peripheral blood.

P Gassó, N Rodríguez, A Martínez-Pinteño, G Mezquida, M Ribeiro, J González-Peñas, I Zorrilla, L Martínez-Sadurni, R Rodriguez-Jimenez, I Corripio and 12 more

Open access · goldAbstract read
In one paragraph

Article in Translational psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 17 institutions in 1 country.

P Gassó *Department of Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain.ORCID http://orcid.org/0000-0001-6930-3454
N Rodríguez *Department of Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain.ORCID http://orcid.org/0000-0002-9618-9383
A Martínez-PinteñoDepartment of Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain.
G MezquidaDepartment of Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain.
M RibeiroDepartment of Psychiatry, Complejo Hospitalario de Navarra, Pamplona, Spain.
J González-PeñasCentro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Madrid, Spain.ORCID http://orcid.org/0000-0002-3850-3012
I ZorrillaCentro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Madrid, Spain.
L Martínez-SadurniHospital del Mar Medicar Research Institute (IMIM), Barcelona, Spain.
R Rodriguez-JimenezCentro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Madrid, Spain.
I CorripioCentro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Madrid, Spain.
S SarróCentro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Madrid, Spain.ORCID http://orcid.org/0000-0003-1835-2189
A IbáñezCentro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Madrid, Spain.ORCID http://orcid.org/0000-0003-2751-0150
J UsallEtiopatogènia i tractament dels trastorns mentals greus (MERITT) Institut de Recerca Sant Joan de Déu Parc Sanitari Sant Joan de Déu, Barcelona, Spain.
A LoboCentro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Madrid, Spain.ORCID http://orcid.org/0000-0002-9098-655X
C MorenCellex, IDIBAPS, University of Barcelona-Hospital Clínic of Barcelona, Barcelona, 08036, Spain.
M J CuestaDepartment of Psychiatry, Complejo Hospitalario de Navarra, Pamplona, Spain.
M ParelladaCentro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Madrid, Spain.
A González-PintoCentro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Madrid, Spain.
E BerrocosoNeuropsychopharmacology and Psychobiology Research Group, Department of Psychology, University of Cádiz, Cádiz, Spain.
M BernardoInstitut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPs), Barcelona, Spain. bernardo@clinic.cat.ORCID http://orcid.org/0000-0001-8748-6717
S MasDepartment of Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain. sergimash@ub.edu.ORCID http://orcid.org/0000-0003-3336-6298
2EPs Group
Centro de Investigación Biomédica en Red de Salud Mental · ESComplejo Hospitalario de Navarra · ESHospital General Universitario Gregorio Marañón · ESUniversidad Complutense de Madrid · ESUniversitat Autònoma de Barcelona · ESUniversity of the Basque Country · ESConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESUniversidad de Alcalá · ESUniversidad de Zaragoza · ESHospital Sant Joan de Déu Barcelona · ESUniversidad de Oviedo · ESUniversitat de València · ESHospital Clínic de Barcelona · ESHospital Del Mar · ESParc Sanitari Sant Joan de Déu · ESUniversidad de Cádiz · ESUniversitat Internacional de Catalunya · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Little is known about the pathophysiological mechanisms of relapse in first-episode schizophrenia, which limits the study of potential biomarkers. To explore relapse mechanisms and identify potential biomarkers for relapse prediction, we analyzed gene expression in peripheral blood in a cohort of first-episode schizophrenia patients with less than 5 years of evolution who had been evaluated over a 3-year follow-up period. A total of 91 participants of the 2EPs project formed the sample for baseline gene expression analysis. Of these, 67 provided biological samples at follow-up (36 after 3 years and 31 at relapse). Gene expression was assessed using the Clariom S Human Array. Weighted gene co-expression network analysis was applied to identify modules of co-expressed genes and to analyze their preservation after 3 years of follow-up or at relapse. Among the 25 modules identified, one module was semi-conserved at relapse (DarkTurquoise) and was enriched with risk genes for schizophrenia, showing a dysregulation of the TCF4 gene network in the module. Two modules were semi-conserved both at relapse and after 3 years of follow-up (DarkRed and DarkGrey) and were found to be biologically associated with protein modification and protein location processes. Higher expression of DarkRed genes was associated with higher risk of suffering a relapse and early appearance of relapse (p = 0.045). Our findings suggest that a dysregulation of the TCF4 network could be an important step in the biological process that leads to relapse and suggest that genes related to the ubiquitin proteosome system could be potential biomarkers of relapse.

Indexed as

SchizophreniaGene ExpressionGene Expression ProfilingHumansLongitudinal StudiesRecurrence

Identifiers

PMID34667144
PMCPMC8526619
OpenAlexW3207694013

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.